RPL5

Across TCGA pan-cancer cohorts, RPL5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RPL5 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher RPL5 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, THCA, and LUSC are the cancer types where RPL5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.619	.002	36	view →
THCA	DFS	Median	All	0.131	0.842	.001	18	view →
LUSC	OS	Median	All	0.168	0.675	.021	18	view →
HNSC	OS	Median	III,IV	0.245	0.726	.021	18	view →
GBM	DFS	Median	All	0.052	0.242	.011	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RPL5–UCEC (DFS)

Open the UCEC breakdown →